Telix Reports US$186M Q1 Revenue, Up 62% YOY

  • Telix Pharmaceuticals reported strong Q1 2025 revenue of $186 million, up 62% year-on-year, driven by Illuccix\u00ae sales and RLS Radiopharmacies acquisition.